Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

253

Enrollment

INDUSTRY

Sponsor class

Conditions

Pre-Exposure Prophylaxis of HIV Infection

Interventions

DRUG: Lenacapavir Tablet
DRUG: Lenacapavir Injection
DRUG: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)

Sponsor

Gilead Sciences

Collaborators

[object Object]